|
|
|
|
Tapentadol immediate release: a new treatment option for acute pain management
Afilalo M et al.Tapentadol is a novel, centrally acting analgesic with 2 mechanisms of action, muopioid receptor agonism and norepinephrine reuptake inhibition. The analgesic effects of tapentadol are independent of metabolic activation and ...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented At American Academy of Pain Medicine Annual Meeting
Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be discussed during the poster sessions of...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO Following are details about the presentations, which are supported by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.(J&JPRD). Tapentadol ER is an investigational, centrally acting oral analgesic that binds to...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
Companies mentioned in this article: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.SAN ANTONIO, Feb. 4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be discussed during the poster sessions of...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO, Feb.4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO Following are details about the presentations, which are supported by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.(J&JPRD). WHAT: Poster 166: Poster 125: Poster 112: WHEN: Wednesday, February 3 from 5:00 to 6:30 p...
|
|
|
Tapentadol Extended Release Data to Be Presented at American Academy of Pain Medicine Annual Meeting
SAN ANTONIO Following are details about the presentations, which are supported by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.(J&JPRD). Tapentadol ER is an investigational, centrally acting oral analgesic that binds to...
|
|
|
Tapentadol hydrochloride: A centrally acting oral analgesic
Wade WE et al.Tapentadol produces analgesia through a dual mechanism of action: muopioidreceptor activation and norepinephrine reuptake inhibition. Its efficacy has been reported in a number of animal studies, as well as in Phase II/III clinical...
|
|
|
Dose Conversion Between Tapentadol Immediate and Extended Release for Low Back Pain
Etropolski MS et al.Dose Conversion Between Tapentadol Immediate and Extended Release for Low Back Pain.
|
|
|
J&J's net declines by 5.3% to $12.3 billion during 2009
Johnson & Johnson (J&J) has suffered setback during the year ended December 2009 on account of litigation matters and lower sales.The company's net earnings declined by 5.3 per cent to US$12,266 million from $12,949 million in the previous year.
|
|
|
Is Tapentadol an Advance on Tramadol?
Guay DRP Oral tapentadol hydrochloride (HCl) is the second combination muopioidreceptor agonist and monoaminereuptake inhibitor to be approved by the Food and Drug Administration (approved for treatment of moderatetosevere acute pain in adults).Oral ...
|
|
|
J&J seeks US FDA nod for pain drug tapentadol extended release tabs
Johnson & Johnson Pharmaceutical Research & Development, LLC has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management...
|
|
|
New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
See more news releases in: Medical Pharmaceuticals, Pharmaceuticals, FDA Approval RARITAN, N.J., Dec.1 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug...
|
